Key Points
Analysts expect $0.60 EPS and $1.03B revenue on May 7.
Solvay's net income fell 86.5% last year despite strong free cash flow growth.
P/E ratio of 101.7 is extremely elevated with weak 2.46% ROE.
Meyka rates SOLB.BR grade B, suggesting neutral fundamentals and hold positioning.
Solvay SA, the Brussels-based specialty chemicals giant, reports earnings on May 7, 2026. Analysts project SOLB.BR will deliver earnings per share of $0.60 and revenue of $1.03 billion. The company operates across four segments: Materials, Chemicals, Solutions, and Corporate Services, serving aerospace, automotive, electronics, and industrial markets. With a market cap of $2.95 billion and 90,000 employees worldwide, Solvay faces mixed signals heading into this report. Recent financial data shows declining profitability trends, but free cash flow improved significantly. Investors will scrutinize whether management can stabilize earnings and justify the current valuation.
Earnings Estimates and What They Mean
Analysts expect Solvay to report $0.60 EPS and $1.03 billion in revenue for the upcoming period. These estimates matter because they set the bar for a beat or miss. The current EPS estimate of $0.60 represents a significant recovery from the trailing twelve-month EPS of just $0.28, suggesting analysts believe the company is turning a corner.
Revenue Outlook
The $1.03 billion revenue estimate reflects modest expectations for the specialty chemicals sector. Solvay’s trailing revenue per share stands at $45.42, indicating strong sales generation despite profitability challenges. The revenue estimate suggests stability rather than explosive growth, which aligns with the company’s mature market position in chemicals and advanced materials.
EPS Recovery Signal
The projected $0.60 EPS is more than double the trailing EPS of $0.28. This dramatic improvement signals either strong operational performance or favorable comparisons to a weak prior year. Investors should watch whether this recovery is sustainable or driven by one-time benefits. The company’s net profit margin of just 0.61% shows how thin earnings are relative to sales.
Historical Performance and Trend Analysis
Solvay’s recent financial history reveals a company under pressure. Full-year 2025 data shows revenue declined 7.5% year-over-year, while net income plummeted 86.5%. Earnings per share fell 86.3%, indicating severe profitability erosion. However, free cash flow grew 22.4%, suggesting the company is managing cash better despite lower profits.
Declining Profitability Trend
The company’s operating income dropped 28.5% in the latest period, while gross profit fell 12.5%. These declines reflect both lower sales and margin compression. The effective tax rate of 77% is unusually high and warrants investigation, as it significantly impacts net income. This suggests the company may have faced one-time tax charges or valuation adjustments.
Cash Flow Strength
Despite earnings weakness, Solvay generated strong free cash flow of $4.14 per share. Operating cash flow reached $6.06 per share, providing a cushion for dividends and debt service. The company maintains a dividend yield of 8.6%, which is attractive but raises questions about sustainability given earnings pressure.
Key Metrics and Valuation Context
Solvay trades at a P/E ratio of 101.7, which is extremely elevated relative to earnings quality. The price-to-sales ratio of 0.62 is more reasonable, suggesting the market values the company’s revenue base. The enterprise value of $4.58 billion represents a 1.55x multiple of sales, typical for specialty chemical companies.
Debt and Financial Health
The company carries significant leverage with a debt-to-equity ratio of 2.13. Net debt to EBITDA stands at 2.22x, indicating moderate financial risk. Interest coverage of 4.36x is adequate but not comfortable. The current ratio of 1.17 suggests adequate short-term liquidity, though the quick ratio of 0.85 shows reliance on inventory conversion.
Return Metrics
Return on equity of 2.46% is weak, reflecting poor profitability relative to shareholder capital. Return on assets of 0.47% is similarly concerning. These low returns explain why the stock has declined 17.6% over the past year despite a 21% gain over ten years. The company must improve operational efficiency to justify its valuation.
What Investors Should Watch
The May 7 earnings call will reveal management’s strategy for reversing profitability declines. Investors should focus on segment performance, margin trends, and guidance for the remainder of 2026. Any commentary on cost reduction initiatives or pricing power will be critical.
Segment Performance
The Materials segment, serving aerospace and electronics, typically carries higher margins. The Chemicals segment, producing soda ash and hydrogen peroxide, faces commodity pricing pressure. Solutions segment performance in specialty chemicals will indicate demand trends. Watch for any segment showing unexpected weakness or strength.
Guidance and Outlook
Management guidance for 2026 will be crucial. If the company projects continued revenue declines, the stock could face pressure despite the earnings beat. Conversely, stabilization or growth guidance could support the valuation. Pay attention to commentary on end-market demand, particularly in automotive and aerospace.
Capital Allocation
With free cash flow of $4.14 per share and a dividend of $2.43 per share, the company has limited room for acquisitions or share buybacks. Watch for any announcements regarding debt reduction or capital expenditure plans.
Final Thoughts
Solvay SA faces mixed fundamentals ahead of its May 7 earnings report. While EPS is expected to recover to $0.60 from $0.28, revenue declined 7.5% and net income fell 86.5% last year, indicating structural challenges in specialty chemicals. Free cash flow grew 22.4% and the dividend yield is strong at 8.6%, but the elevated P/E ratio of 101.7 offers little margin for error. Investors should watch whether management can stabilize revenue and improve margins, as current profitability levels cannot sustain this valuation.
FAQs
What EPS and revenue do analysts expect from Solvay?
Analysts project Solvay will report $0.60 EPS and $1.03 billion in revenue. The EPS estimate more than doubles the trailing EPS of $0.28, signaling expected improvement. Revenue expectations suggest stability in specialty chemicals markets.
Why did Solvay’s earnings decline so sharply last year?
Net income fell 86.5% due to a combination of 7.5% revenue decline and margin compression. Operating income dropped 28.5% while gross profit fell 12.5%. An unusually high 77% effective tax rate also significantly impacted net earnings.
Is Solvay’s dividend safe given weak earnings?
The 8.6% dividend yield is attractive but faces sustainability questions. Free cash flow of $4.14 per share covers the $2.43 dividend, but declining profitability trends warrant caution. Watch management guidance on capital allocation.
What does Meyka’s B grade mean for Solvay?
Meyka AI rates SOLB.BR with a grade of B, indicating neutral fundamentals. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. It suggests holding rather than buying or selling.
What should investors watch during the earnings call?
Focus on segment performance, margin trends, and 2026 guidance. Listen for commentary on cost reduction, pricing power, and end-market demand in aerospace and automotive. Any revenue stabilization signals would be positive for the stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)